Popular Trader Joe's Salad Recalled in 18 States Due to Undeclared Allergen
Related: Are Food Recalls Really on the Rise? A Food Microbiologist Weighs In
Per the FDA, the salads are being recalled because the topping packet may potentially contain an undeclared milk allergen. In other words, the product may contain milk that is not listed on the ingredients label. The 500 recalled salads were mistakenly packaged with a sealed packet of Parmesan cheese crumbles, instead of a packet of crispy onions. The salads were produced by Taylor Fresh Foods Illinois, and have the 'Use By' date of April 28, 2025, or April 29, 2025. The UPC of the recalled salads is 00773164.
Additionally, the FDA noted that the now-recalled salads were distributed to Trader Joe's stores in 18 states. The states impacted by this recall are Alabama, Iowa, Illinois, Indiana, Kansas, Kentucky, Michigan, Minnesota, Missouri, North Carolina, Nebraska, New Jersey, New York, Ohio, Pennsylvania, South Carolina, Tennessee, and Wisconsin.
Related: The Top 6 Causes of Food Recalls—and the States Most Often Impacted
Individuals with a sensitivity or allergy to milk may be at risk of an adverse reaction if they consume these salads, but the FDA points out that there have been no reported adverse reactions to this product to date.
Still, the FDA is urging customers who purchased Trader Joe's Sesame Miso Salad with Salmon with the 'Use By' dates of April 28, 2025 or April 29, 2025 in the aforementioned states to discard the product if they have a milk allergy or dairy sensitivity.
Shoppers with questions about this recall may contact Taylor Fresh Foods customer service at (855) 455-0098, Monday through Friday between 8 a.m. and 5 p.m. PST.
Related: What to Do If You Have Recalled Food In Your Kitchen
Read the original article on Real Simple
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
29 minutes ago
- New York Times
What Happens When Doctors Can't Trust the Government?
The other day I was talking to one of my patients about her vaccinations, and I noticed that she hadn't had a Covid-19 vaccine since the early days of the pandemic. 'The virus has changed so much since then,' I told her, 'so we recommend that you get the current vaccine——' And then I stopped dead in my tracks, the words 'we recommend' lingering in the air. This is how I'd always phrased these types of recommendations, but I was suddenly unsure of who the 'we' was. Up until recently, it meant a medical community that included not just my health care colleagues, but also the Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institutes of Health, respected medical journals and the research community. It's not remotely feasible for practicing clinicians to review every medical study out there, so we rely on trusted colleagues and institutions with the relevant expertise to help guide us. The 'we' suddenly rang hollow. The institutions I trusted to be deliberative and evidence-based sources of knowledge that extend my medical abilities are no longer that. In the first Trump administration, despite relentless attacks from the president, the nation's public health institutions remained largely intact, if wearied. But the plunder of the second Trump administration has disemboweled them and installed fox-guarding-the-henhouse leadership. Medical professionals can no longer fully trust federal health guidance, and our patients are the ones who will suffer the most. For most of my colleagues and me, the C.D.C. and the N.I.H. were the medical Mount Olympus, the towering pillars of medical authority. Contrary to right-wing portrayals, these were not dictatorial authorities. These were earned authorities, comprising our best, brightest and most dedicated peers. The formidable talents of these doctors and scientists would have commanded enviable salaries had they taken jobs in industry, but they chose the public sector instead — something that we clinicians were forever grateful for. Were there egos, missteps and shortcomings? Sure. But by and large, the people I met who worked for the C.D.C. or N.I.H. were brilliant and rigorous, and cared passionately about the science they were pursuing. While there are some doctors who viewed our public health institutions with disdain — some of them now are running these very organizations — most practicing physicians relied heavily on them to deliver the best care possible to their patients, despite occasional quibbles. What a relief, I always felt, that there were people organizing the things I can't do — testing new treatments, conducting population studies, keeping tabs on worldwide diseases, issuing guidelines and more. Want all of The Times? Subscribe.
Business Insider
11 hours ago
- Business Insider
Sarepta says eight-year-old death deemed unrelated to Elevidys
Sarepta (SRPT) said in a statement Friday night: 'Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy patient who had received Elevidys gene therapy. The death of this patient was deemed unrelated to treatment with Elevidys…Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. Elevidys is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy.' Elevate Your Investing Strategy:
New York Post
11 hours ago
- New York Post
Breakthrough as two FDA-approved drugs are found to reverse Alzheimer's — including restoring memory
In a stunning scientific discovery, researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. And the best part of all? Both are already FDA-approved — albeit for cancer. Researchers first pinpointed how Alzheimer's disease scrambles gene activity in individual brain cells. 3 Researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. Pixel-Shot – Using the Connectivity Map database of 1,300 FDA‑approved drugs, the researchers looked for medications that reverse Alzheimer's‑associated gene expression — landing on a shortlist of five, and zeroing in on two cancer drugs. In what one researcher called a 'mock clinical trial,' they then mined 1.4 million patients' medical records, finding that those who had taken letrozole or irinotecan for cancer were significantly less likely to develop Alzheimer's. When given together in an aggressive Alzheimer's mouse model, letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Most importantly, they restored memory and learning in mice that had already developed severe symptoms. It's an exciting development for an illness that's notoriously tricky. 3 Letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Eric Hood – 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly,' Marina Sirota, the interim director of the UCSF Bakar Computational Health Sciences Institute, said in a statement. 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. 'This makes it very challenging for drug development — which traditionally produces one drug for a single gene or protein that drives disease.' 3 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. yurakrasil – The findings were published in the journal Cell. Both drugs are already FDA‑approved for other uses, which could dramatically speed up the path to human trials. However, because they are cancer drugs, repurposing them may be complex and risky. This finding adds to a growing number of potential Alzheimer's treatments. A compound found in rosemary and sage — carnosic acid — has been shown to reverse memory loss and reduce brain inflammation in mice with Alzheimer's, bringing their cognitive function back to near-normal levels. A study from Stanford Medicine found that seniors who received the shingles vaccine were 20% less likely to develop dementia over seven years. And researchers at Penn State and Stanford University discovered that a certain cancer drug could restore memory and brain function in early stage Alzheimer's models.
